xCures News Collection

Endeavor BioMedicines Partners with xCures to Identify Patients with PTCH1 mutations for Phase 2 Trial of ENV-101 (taladegib)

xCures to use tumor sequencing information and its platform to pair patients with available treatment options Endeavor BioMedicines, a clinical-stage biotechnology company targeting the core drivers of terminal diseases including oncology and fibrosis, and xCures, a company that aims to improve cancer outcomes and accelerate cancer research using artificial intelligence,… Read more »

xCures announces real world biomarker study for patients with FGFR-mutant bladder cancer receiving Balversa®

Tyra Biosciences supported study investigates if non-invasive blood and urine samples provide biomarkers to assess clinical response to erdafitinib treatment Today, xCures announced their collaboration with Tyra Biosciences for a real-world biomarker study involving patients with FGFR-mutant bladder cancer receiving Balversa® (erdafitinib) as their standard of care medical therapy. The… Read more »

xCures and BioSpark partner to boost Real World Oncology Data offerings

New partnership allows for a 40,000+ patient dataset to unlock new insights into cancer treatments and outcomes. xCures, Inc. and BioSpark, Inc. are proud to announce their strategic partnership to harmonize and commercialize a joint oncology Real World Data (RWD) offering. The partnership unlocks new insights into the treatment and… Read more »